Regencell Bioscience Holdings Ltd (RGC) company profile
Close on Nov 18, 2026Market cap $2.33BP/E –Yield –
About Regencell Bioscience
Medicinal Chemicals & Botanical Products, SIC 2833
Regencell Bioscience Holdings Limited is an early-stage bioscience firm that researches, develops, and commercializes traditional Chinese medicine (TCM) formulas. The company focuses on formulas designed to treat neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). It operates primarily through its subsidiary, Regencell Bioscience Limited, in partnership with an experienced practitioner to develop standardized liquid-based formulations. The target patient population and end customers consist of individuals diagnosed with ADHD and ASD, along with their families and caregivers seeking alternative or holistic treatment options.
The company maintains its principal executive offices in Causeway Bay, Hong Kong, and holds corporate registration in the Cayman Islands. Its operations and clinical research activities are based primarily in Hong Kong, where it conducts efficacy trials with enrolled pediatric patients and collaborates with local practitioners. In addition to its active research entity, the organization maintains wholly owned corporate subsidiaries incorporated in Hong Kong and the British Virgin Islands for future operational needs.
Summary of the business section of Regencell Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Regencell Bioscience Holdings Ltd
- Founded
- 2014
- Headquarters
- Hong Kong, China
- Address
- 9/F Chinachem Leighton Plaza, 29 Leighton Road, Causeway Bay
- Phone
- 852 2155 0823
- Website
- regencellbioscience.com
- Employees
- 13, Jun 30, 2021
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- E9
- Auditor
- HTL International, LLC, Houston, Texas
Stock & identifiers
- Ticker
- RGC
- Exchange
- Nasdaq
- IPO date
- Jul 20, 2021
- Shares outstanding
- 496M, Jun 30, 2026
- Filer category
- Large accelerated filer
- Stock splits
- 38-for-1, Oct 31, 2025; 38-for-1, Jun 16, 2025
- SEC CIK
- 1829667
- CUSIP
- G7487R100
- FIGI
- BBG00ZS40360
- Share class FIGI
- BBG00ZS40379
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yat-Gai Au | Chief Executive Officer, Director | 437,896,116 |
| James Wai Hong Chung | COO and Chief Strategy Officer, Director | – |
| Ho Yau Chan | Financial Controller | – |
| Yat-Pui Au | Chief Business Officer | 581,514 |
| William Wing Yan Dr Lo | Director | 485,629 |
| Evana Yee Wah Hui | Director | – |
| Margaret Hoor Han Lo | Director | 604,050 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 20, 2021
- Offer price
- $9.50
- Exchange
- Nasdaq
- First trading day
- Jul 19, 2021
- First-day close
- $9.56+0.6%
- Lock-up ends (est.)
- Jan 15, 2022
“Per Share Total Public offering price $ 9.50 $ 21,850,000 Underwriter discount (1) $ 0.7125 $ 1,638,750 Proceeds to us, before expenses $ 8.7875 $ 20,211,250 (1) We have agreed to reimburse the underwriter for certain expenses.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 20, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 15, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?